BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
Sampling strategy to test for presence of mycoplasma in cell therapies
read more
High Level Analytics
Viewing related articles
Empty/full Capsids (AAV / LVV) testing strategies
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.
Approaches to testing allogeneic cell therapies for adventitious viral contaminants
A BioPhorum member survey examining approaches to testing allogenic cell therapies for adventitious viral contaminants.
High Level Analytics workstream rcAAV testing strategies survey
A member only survey to benchmark industry experience with replication competent AAV testing. The outcome of the survey will help stimulate further discussion of the topic within the workstream.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community​
A BioPhorum member only summary document detailing consolidated feedback and suggested recommendations from the High-Level Analytics team on MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community​.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community​
Summary of member feedback and recommendations on British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community. A member only document.
Challenges for potency assay development for in vivo and ex vivo gene therapies and the matrix approach
This paper highlights some of the challenges to develop potency assays for gene therapies and promotes a potential solution. It seeks to establish Industry alignment on the benefits of a matrix approach and provides high level guidance on how to adopt this strategy towards potency assay development and validation with examples for in vivo and ex vivo GT processes.